Cargando…
Prostaglandin D(2) as a mediator of lymphopenia and a therapeutic target in COVID-19 disease
A characteristic feature of COVID-19 disease is lymphopenia. Lymphopenia occurs early in the clinical course and is a predictor of disease severity and outcomes. The mechanism of lymphopenia in COVID-19 is uncertain. It has been variously attributed to the release of inflammatory cytokines including...
Autores principales: | Gupta, Ajay, Chander Chiang, Kate |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373045/ https://www.ncbi.nlm.nih.gov/pubmed/32759007 http://dx.doi.org/10.1016/j.mehy.2020.110122 |
Ejemplares similares
-
Treatment of COVID-19 Pneumonia and Acute Respiratory Distress With Ramatroban, a Thromboxane A(2) and Prostaglandin D(2) Receptor Antagonist: A Four-Patient Case Series Report
por: Ogletree, Martin L., et al.
Publicado: (2022) -
Lymphopenia, Lymphopenia-Induced Proliferation, and Autoimmunity
por: Sheu, Ting-Ting, et al.
Publicado: (2021) -
To zinc or not to zinc for COVID-19 prophylaxis or treatment?
por: Chiang, Kate Chander, et al.
Publicado: (2021) -
Aspirin Resistance in Obese and Elderly Patients with COVID-19?
por: Chiang, Kate Chander, et al.
Publicado: (2021) -
Transpulmonary Bubble Transit in Severe COVID-19: Pulmonary Vasodilatation or Angiogenesis?
por: Chiang, Kate Chander, et al.
Publicado: (2021)